Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency

by Barry101 | Jul 14, 2016 | Press Release

PHILADELPHIA, July 14, 2016 — Hemispherx Biopharma (NYSE:HEB) (“Hemispherx” or the “Company”) today announced key elements of its strategic growth plan as well as additional measures being implemented under the Company’s commitment...

Hemispherx Updates the Status of the Alferon® Manufacturing Facility

by Barry101 | Jul 11, 2016 | Press Release

PHILADELPHIA, July 11, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) in response to various questions about the status of the work to repair damage to our Alferon®  Manufacturing  facility caused by the flood of January 5, 2016 is pleased to provide...

Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obtaining Commitments of $3.5 Million in Payments to Company

by Barry101 | Jun 8, 2016 | Press Release

CEO Says Series of Coordinated Settlements Should Allow the New Management Team to Focus Exclusively on the Company’s Long-Term Commercial, Research and Financial ObjectivesPHILADELPHIA, June 08, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) is pleased...

Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology

by Barry101 | Jun 7, 2016 | Press Release

Article Reviews the History of Drug Development, Patient Clinical Trials, and Evaluates Toxicity of the ProductPHILADELPHIA, June 07, 2016 — Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma (NYSE MKT:HEB) and a...

Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property

by Barry101 | Jun 6, 2016 | Press Release

PHILADELPHIA, June 06, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights (IP) of  William A. Carter, M.D., the former CEO of Hemispherx. Further, all...

Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm

by Barry101 | May 31, 2016 | Press Release

Initial Target is ANMAT Approval to Treat Chronic Fatigue Syndrome Patients in ArgentinaPHILADELPHIA, May 31, 2016 — Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for...